HLS Therapeutics Inc. provided consolidated earnings guidance for the fiscal year 2024. for the year, the company expects consolidated revenue of $63.5 million-66.5 million, or 1%-5% growth.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
3.35 CAD | +0.75% |
|
-2.47% | -15.19% |
06-07 | Transcript : HLS Therapeutics Inc. - Shareholder/Analyst Call | |
05-28 | HLS Therapeutics Notes Role of Pharmaceutical Support Programs on Persistence with Clozapine Treatment in Quebec Study | MT |
![Consensus](/images/consensus_flch.gif)
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-15.19% | 77.82M | |
+26.15% | 75.76B | |
-2.46% | 23.95B | |
+14.23% | 8.7B | |
+1.47% | 8.29B | |
-32.92% | 6.7B | |
+18.62% | 5.38B | |
+1.10% | 4.08B | |
-9.24% | 3.79B | |
-10.20% | 3.3B |
- Stock Market
- Equities
- HLS Stock
- News HLS Therapeutics Inc.
- HLS Therapeutics Inc. Provides Consolidated Earnings Guidance for the Fiscal Year 2024